CBD inhalation significantly reduced expression of IDO and cGAS, two immune regulators implicated in Alzheimer's neuroinflammation, along with decreasing proinflammatory cytokines in a transgenic mouse model.
Alzheimer's researchers, neuroscientists studying neuroinflammation, and scientists investigating CBD's molecular mechanisms.
CBD simultaneously reduced two distinct neuroinflammation pathways
What the researchers found
CBD treatment reduced both IDO and cGAS expression in the brains of 5XFAD Alzheimer's mice, with corresponding decreases in TNF-alpha, IL-1beta, and IFN-gamma. Bioinformatics identified AKT1, TRPV1, and GPR55 as potential molecular targets.
Why it matters
Alzheimer's research has increasingly recognized neuroinflammation as a driver of disease progression beyond amyloid plaques. Identifying that CBD simultaneously targets two distinct inflammatory pathways offers a mechanistic basis for further investigation.
The numbers in context
CBD significantly reduced IDO and cGAS expression. Proinflammatory cytokines TNF-alpha, IL-1beta, and IFN-gamma all decreased. Three molecular targets identified: AKT1 (cell survival signaling), TRPV1 (neuroinflammation), GPR55 (immune cell activation).
How the study worked
5XFAD transgenic Alzheimer's mouse model treated with inhaled CBD. Outcomes measured by flow cytometry, immunofluorescence, gene expression analysis, and STRING-based bioinformatics for target identification.
What this study cannot tell us
Mouse model only, using a transgenic strain that overexpresses Alzheimer's mutations not typical of most human cases. Inhaled CBD dosing in mice may not translate to human administration. Bioinformatics predictions of molecular targets need experimental validation.
How to read the evidence
Transgenic mouse study with multiple analytical methods provides mechanistic insight, but uses an aggressive Alzheimer's model and has not been replicated in humans.
When this study was published
Published in 2025.
The bigger picture
Most Alzheimer's drugs have targeted amyloid or tau. The growing recognition that immune dysfunction contributes to neuronal damage opens new therapeutic avenues, and CBD's multi-target anti-inflammatory profile makes it an interesting candidate.
Questions still open
- Would CBD show similar effects in other Alzheimer's models? Can these inflammatory biomarkers serve as treatment response markers in human trials?
Common questions
Could CBD help with Alzheimer's disease?
How does CBD reduce brain inflammation in this study?
Read the original research
Rethinking Alzheimer's: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control.
eNeuro, 12(10)
Citation
Emami Naeini, Sahar; Bhandari, Bidhan; Hill, Breanna; Perez-Morales, Nayeli; Rogers, Hannah M; Khodadadi, Hesam; Young, Nancy; Maciel, Lívia Maria; Yu, Jack C; Hess, David C; Morgan, John C; Lopes Salles, Évila; Wang, Lei P; Baban, Babak. (2025). Rethinking Alzheimer's: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control.. eNeuro, 12(10). https://doi.org/10.1523/ENEURO.0114-25.2025
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk